- Dec 31, 2021
Miami Debates in Hematologic Malignancies Jan 27, 2022
It is our great pleasure to welcome you to The Miami Debates in Hematologic Malignancies virtual conference which will take place on January 27, 2022.
The aims of the conference are to provide an up-to-date review of the latest news in the field of hematologic malignancies. The content of the meeting will focus on clinical management. Also, novel scientific data will be reviewed and discussed from a clinical perspective. The format of the meeting will be a combination
146
- Dec 29, 2021
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cells, manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed and refractory multiple myeloma Sponsor Novartis Pharmaceuticals ClinicalTrials.go
245
- Dec 23, 2021
NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function
DREAMM 12 Relapsed & Refractory Myeloma NCT04398745: Phase 1: A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function (DREAMM 12) Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and majority of MM participants are either at r
188
- Dec 20, 2021
NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma Drug: REGN5458 Sponsor Regeneron Pharmaceuticals ClinicalTrials.gov Identifier: NCT05164250 Official Title: Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Mul
172
- Dec 17, 2021
NCT05064358: Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)
NCT05064358: Phase 2 - Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14) This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both. Sponsor GlaxoS
150
- Dec 16, 2021
NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT
NCT05130827: Phase 2: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) NCT05130827: Phase 2: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrasti
78
- Dec 16, 2021
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
BMT CTN 1902 NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902 MM CAR-T to Upgrade Response BMT CTN 1902 This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM). Sponsor Marcelo Pasquini, MD Collaborators National Heart, Lung, and Blood Insti
145
- Dec 16, 2021
NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM
FUMANBA-1 NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1) A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1) (FUMANBA-1) This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM. Spo
101
- Dec 16, 2021
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With RRMM (MoMMent)
NCT05160584: A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent) NCT05160584: A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent) The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety of current standard of care (SOC) antimyeloma treatments in participants with previous
35
- Dec 16, 2021
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
Talquetamab Phase 1b study NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens. Sponsor Janssen Research & Development, LLC Multiple locations International Study ClinicalTrials.gov Identifier: NCT0505009
334
- Dec 15, 2021
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy The aim of this study is to evaluate the feasibility of a digital health coaching program for, and to describe quality of life of, individuals in the 6 months following chimeric antigen receptor (CAR) T cell therapy. Up to 50 English-speaking individuals aged 18 and older who are to receive treatment with a CAR T cell therapy will be enrolled, all at The Univer
80
- Dec 15, 2021
Multiple Myeloma Research Foundation - MMRF's The Right Track Program | High Impact Topic (HIT)
MMRF's The Right Track(TM) Program: This HIT shows patients who have been diagnosed with multiple myeloma how to get on the right treatment path to their best outcome as quickly as possible. Multiple Myeloma Research Foundation - MMRF's The Right Track Program | High Impact Topic (HIT) Learn more: MMRF Resources https://themmrf.org/multiple-myeloma/resources/ Multiple Myeloma Research Foundation https://themmrf.org Multiple Myeloma Research Foundation - MMRF Videos Watch on Y
163
- Dec 12, 2021
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd
The INSURE Study 2701 The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Adults, Clinical Research, Health Outcomes Research, Plasma Cell Disorders
149
- Dec 12, 2021
Siteman Cancer Center: Learn about cancer clinical trials and the benefits they offer patients
Siteman Cancer Center: Learn about cancer clinical trials and the benefits they offer patients Siteman Cancer Center https://www.youtube.com/user/SitemanCancerCenter/videos
96
- Dec 11, 2021
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma 1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Program: Oral and Poster Abstracts Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I Hematology Disease Topics & Pathways: Biological,
63
- Dec 11, 2021
Multiple Myeloma Research Foundation - MMRF - Immunotherapy
Multiple Myeloma Research Foundation - MMRF - Immunotherapy | High Impact Topic (HIT) Immunotherapy: Understand how your immune system interacts with your myeloma, and how new immunotherapies are helping patients’ immune systems recognize and destroy myeloma cells. Multiple Myeloma Research Foundation - MMRF - Immunotherapy | High Impact Topic (HIT) Learn more: MMRF Resources https://themmrf.org/multiple-myeloma/resources/ Multiple Myeloma Research Foundation https://themmrf.
173
- Dec 10, 2021
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma A Phase1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral irreversible menin inhibitor, in adult patients with acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma Sponsor Biomea
59
- Dec 10, 2021
NCCN Animation for Patients: What is Multiple Myeloma?
NCCN Animation for Patients: What is Multiple Myeloma? Learn more: https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients
146
- Dec 10, 2021
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Sponsor Pack Health Collaborators M.D. Anderso
63